Abstract 533P
Background
Oligodendrogliomas are rare tumors and affect young people. In 2016, the new WHO classification was introduced that includes molecular features (IDH mutation and 1p/19q codeletion) that were not present in previous classifications. Currently, there is no data indicating the impact of this new classification on our clinical practice. The objective of this study is to review the clinical evolution of a cohort of patients, before and after reclassification, using molecular criteria.
Methods
Cases with a diagnosis of grade 2 and grade 3 oligodendroglioma and oligoastrocytoma were identified in the registries of two tertiary hospitals. A total of 182 cases, corresponding to a period of 37 years (between 1977 and 2014), were identified and termed initial cohort. Subsequently, IDH mutation and codeletion of 1p/19q analysis were performed in this cohort. A total of 91 patients fulfilled these characteristics and were termed the reclassified cohort. The clinical evolution of both cohorts was analyzed.
Results
The mean age of the cohort was 45 years (14-75), with a Males: Female ratio of 61%/39%. Frontal lobe location 60%, 65% grade 2 and 22% oligoastrocytomas. Complete resection 47% (subtotal 22%, partial 20%, biopsy 7%). After surgery, 50% received radiotherapy, 30% chemotherapy, 36% did not receive adjuvant therapy. The median follow-up was 9 years. Unlike what was observed in the initial cohort, there were no statistical differences in median overall survival (OS) in the reclassified cohort regardless of grade; grade 2, 13.3y (95%CI 8.2-18.4), grade3, 12 years (95%CI 5.6-18.3), therefore, grade loses its prognostic impact with the new molecular classification. OS in the excluded cohort was 7.52years (95%CI 4.67-10.38). The OS in those cases without adjuvant treatment was 12 years. 30% of oligoastrocytomas in the initial cohort were reclassified to oligos.
Conclusions
Molecular classification allows a more accurate selection of oligodendrogliomas and implies that cases have a better prognosis, regardless of grade and treatment received. These data should be taken into account in clinical practice for a better selection of the risks and benefits of adjuvant treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.A. Vaz Salgado: Financial Interests, Personal, Advisory Board: Novocure; Financial Interests, Personal and Institutional, Coordinating PI: Pfizer. J.M. Sepulveda Sanchez: Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: MSD, Novocure, CeCaVa, Cantex; Financial Interests, Personal and Institutional, Research Grant: Pfizer, Cantex. L.L. Ley: Non-Financial Interests, Member, President: Sociedad Española de Neurocirugía; Non-Financial Interests, Member: Grupo Español de Investigaciones Neurooncológicas. A. Carrato Mena: Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Bayer, Merck, MSD, Novartis, Shire. All other authors have declared no conflicts of interest.
Resources from the same session
518P - Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project
Presenter: Federica D'Antonio
Session: Poster session 10
519P - The landscape of PDGFRA mutation in Chinese patients with glioma
Presenter: Qiang Lv
Session: Poster session 10
520P - Copy number variation spectrum analysis of primary glioblastoma
Presenter: Chuandong Cheng
Session: Poster session 10
521P - Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Presenter: Ana Belen Diaz Mendez
Session: Poster session 10
522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis
Presenter: Rashmi Rana
Session: Poster session 10
523P - Analysis of DNA damage response (DDR) gene expression as a prognostic factor for glioblastoma patient mortality
Presenter: Alessia-Tara Droesse
Session: Poster session 10
524P - Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma
Presenter: Jonathan Decarpentrie
Session: Poster session 10
525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Presenter: Lorena Gurrieri
Session: Poster session 10
526P - In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Presenter: Cristina Saiz-Ladera
Session: Poster session 10
527P - Targetable gene fusions and other alterations in central nervous system tumors assessed by RNA and DNA-based next-generation sequencing
Presenter: LEIMING WANG
Session: Poster session 10